查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
1741153

纤维蛋白溶解疗法市场按药物类型、适应症、最终用户、给药方式、分销管道、患者年龄、包装类型、应用、剂型和地区划分

Fibrinolytic Therapy Market By Drug Type, By Indication, By End User, By Administration, By Distribution Channel, By Patient Age, By Packaging Type, By Application, By Dosage Form, By Region
出版日期: | 出版商: Coherent Market Insights | 英文 260 Pages | 商品交期: 2-3个工作天内

价格
简介目录

预计 2025 年纤维蛋白溶解市场规模为 375.9 亿美元，到 2032 年将达到 484.8 亿美元，2025 年至 2032 年的复合年增长率为 3.7%。

报告范围 报告详细信息
基准年 2024 2025年的市场规模 375.9亿美元
效能数据 从2020年到2024年 预测期 2025年至2032年
预测期：2025-2032年复合年增长率： 3.70% 2032年价值预测 484.8亿美元

纤溶疗法用于溶解导致心臟病发作和中风的血栓。虽然它是一种挽救生命的治疗方法，但如果存在潜在健康问题，则可能会失败，并导致其他严重和病症。血栓溶解疗法通常透过静脉注射给药。当患者出现中风或心臟病发作的症状，且对抗凝血剂和类固醇药物等其他治疗无效时，可以使用该疗法。此疗法可以在家中或医院进行。组织纤维蛋白溶酶原活化剂或Alteplase是一种能够分解纤维蛋白和其他构成体内血栓的物质的药物，最常用于血栓溶解疗法。Tenecteplase对部分患者也有效，可以口服。

市场动态

创伤和道路交通事故的增加推动了对抗纤溶药物的需求，从而促进了纤溶治疗市场的成长。口服止血药物（主要用于治疗月经出血，月经量大）的使用日益增多，预计将进一步推动市场成长。此外，严重道路交通事故和创伤性损伤的发生率不断上升，也带来了对抗纤溶药物的需求，推动了市场的成长。此外，这些药物在血友病和血小板功能障碍、血管性血友病、A型血友病和乙型血友病等其他疾病的治疗中得到越来越多的应用，也进一步推动了市场的成长。

全球纤溶疗法市场也受到心血管、神经系统和肺部疾病的盛行率上升所推动，这些疾病会导致血栓形成。根据世界卫生组织 (WHO) 的数据，心血管疾病每年导致超过 1,790 万人死亡。此外，老年人口的成长也促进了市场的成长，老年人更容易患上此类疾病。然而，纤溶药物的高昂价格、严格的监管以及治疗相关的出血风险阻碍了市场的扩张。该市场为开发具有更高特异性、增强纤维蛋白特异性并降低出血风险的有效重组、合成类似物和混合分子提供了机会。

然而，这些药物的高价格是阻碍市场成长的关键因素。

本研究的主要特点

  • 本报告对全球纤维蛋白溶解市场进行了详细分析，并以 2024 年为基准年，展示了预测期 2025-2032 的市场规模和复合年增长率。
  • 它还强调了各个领域的潜在商机，并说明了该市场的有吸引力的投资提案矩阵。
  • 它还提供了有关市场驱动因素、限制因素、机会、新产品发布和核准、市场趋势、区域前景和主要企业采用的竞争策略的重要见解。
  • 它根据公司亮点、产品系列、关键亮点、绩效和策略等参数，介绍了全球纤维蛋白溶解市场的主要企业概况。
  • 本报告的见解可以帮助负责人和公司经营团队就未来的产品发布、类型升级、市场扩张和行销策略做出明智的决策。
  • 全球纤维蛋白溶解市场报告迎合了该行业的各个相关人员，例如投资者、供应商、产品製造商、经销商、新进业者和金融分析师。
  • 相关人员将透过用于分析全球纤维蛋白溶解市场的各种策略矩阵更轻鬆地做出决策。

目录

第一章 调查目的与前提条件

  • 研究目标
  • 先决条件
  • 简称

第二章 市场展望

  • 报告描述
    • 市场定义和范围
  • 执行摘要
  • Coherent Opportunity Map（COM）

第三章市场动态、法规与趋势分析

  • 市场动态
    • 司机
  • 心血管疾病发生率上升
  • 人口老化加剧
  • 技术进步
  • 获得医疗保健设施
    • 限制因素
  • 在某些患者族群中疗效有限
  • 出血併发症的风险
  • 替代治疗方法的可用性
  • 时间敏感性和入院到入针延迟
    • 机会
  • 新兴市场
  • 联合治疗
  • 远端医疗和远端医疗
  • 个人化医疗
    • 主要亮点
    • 监管情景
    • 近期动态
    • 产品发布/核准
    • PEST分析
    • 波特分析
    • 合併、收购和合作

4. 全球纤维蛋白溶解市场-冠状病毒（COVID-19）大流行的影响

  • COVID-19流行病学
  • 供需侧分析
  • 经济影响

5. 全球纤溶疗法市场（以药物类型），2020 年至 2032 年

  • Alteplase
  • 莱泰普拉兹
  • 替奈普利
  • 链球菌激酶
  • 安妮斯特普拉斯
  • 尿激酶

6. 全球纤溶疗法市场（依适应症划分），2020 年至 2032 年

  • 急性缺血性脑中风
  • 急性心肌梗塞
  • 深层静脉栓塞症
  • 週边动脉血栓症
  • 其他动脉血栓症

7. 全球纤维蛋白溶解市场（以最终用户划分），2020 年至 2032 年

  • 医院
  • 门诊手术中心
  • 专科诊所
  • 其他的

8. 全球纤维蛋白溶解市场（依管理部门划分），2020 年至 2032 年

  • 静脉注射（IV）
  • 动脉内（IA）

9. 全球纤维蛋白溶解市场（依通路划分），2020 年至 2032 年

  • 医院药房
  • 零售药局
  • 网路药局

第 10 章。 2020 年至 2032 年按患者年龄分類的全球纤维蛋白溶解市场

  • 成年患者
  • 儿科患者

第 11 章。 2020 年至 2032 年按包装类型分類的全球纤维蛋白溶解市场

  • 管瓶
  • 安瓿
  • 预填充式注射器

第 12 章。 2020 年至 2032 年全球纤维蛋白溶解市场（依应用）

  • 紧急医疗
  • 介入性心臟病学
  • 血栓症治疗
  • 其他的

第 13 章。 2020 年至 2032 年按剂型分類的全球纤溶疗法市场

  • 用于復溶的冻干粉
  • 注射液

第 14 章。 2020 年至 2032 年按地区分類的全球纤维蛋白溶解市场

  • 北美洲
      • 美国
      • 加拿大
  • 欧洲
      • 德国
      • 英国
      • 法国
      • 义大利
      • 西班牙
      • 俄罗斯
      • 其他欧洲国家
  • 亚太地区
      • 中国
      • 印度
      • 日本
      • 澳洲
      • 韩国
      • ASEAN
      • 其他亚太地区
  • 拉丁美洲
      • 巴西
      • 墨西哥
      • 阿根廷
      • 其他拉丁美洲
  • 中东
      • 海湾合作委员会国家
      • 以色列
      • 其他中东地区
  • 非洲
      • 南非
      • 中部非洲
      • 北非

第十五章竞争格局

  • 公司简介
    • Genentech, Inc.（Roche）
    • Bayer AG
    • Boehringer Ingelheim International GmbH
    • Pfizer Inc.
    • Bristol Myers Squibb Company
    • Novarts AG
    • AstraZeneca PLC
    • Johnson &Johnson
    • Daiichi Sankyo Company, Limited
    • Merck &Co., Inc.
    • Sanofi SA
    • Takeda Pharmaceutical Company Limited
    • Abbott Laboratories
    • Mallinckrodt Pharmaceuticals
    • Mitsubishi Tanabe Pharma Corporation

第 16 章 章节

  • 参考
  • 调查方法
  • 关于出版商
简介目录
Product Code: CMI5879

Fibrinolytic Therapy Market is estimated to be valued at USD 37.59 Bn in 2025 and is expected to reach USD 48.48 Bn by 2032, growing at a compound annual growth rate (CAGR) of 3.7% from 2025 to 2032.

Report Coverage Report Details
Base Year: 2024 Market Size in 2025: USD 37.59 Bn
Historical Data for: 2020 To 2024 Forecast Period: 2025 To 2032
Forecast Period 2025 to 2032 CAGR: 3.70% 2032 Value Projection: USD 48.48 Bn

Fibrinolytic therapy is used to dissolve blood clots that cause heart attacks or strokes. It is a lifesaving treatment, but it fails in underlying health problems that can lead to other serious diseases and conditions. Thrombolysis is usually given through an intravenous line. It is used when symptoms of a stroke or heart attack are present and the patient is not responding to other treatments, like anticoagulants and steroid medications. It can be given at home or in a hospital. Tissue plasminogen activator or alteplase is a drug that breaks down fibrin and other substances that create clots in the body that is most commonly used for thrombolysis. The drug tenecteplase is also effective in some patients, and it can also be given by mouth.

Market Dynamic:

The increasing incidences of trauma and road accidents are driving the demand for antifibrinolytic drugs, which in turn is fuelling fibrinolytic therapy market growth. The growing use of these drugs in oral bleeding treatments, mainly for menorrhagia (heavy menstrual flow) is again anticipated to bolster the market growth further. Moreover, rising incidences of severe road accidents and trauma is creating demand for anti-fibrinolytic drugs, thereby propelling the market growth. Furthermore, rising adoption of these drugs for treating hemophilia and other conditions such as platelet dysfunctions, Von Willebrand diseases and haemophilia A and B is further bolstering the market growth.

Also, the global fibrinolytic therapy market is driven by the rising prevalence of cardiovascular diseases, neurological disorders and pulmonary diseases causing blood clots. As per World Health Organization (WHO), cardiovascular diseases accounts for over 17.9 Mn deaths annually. Moreover, growing geriatric population prone to such diseases contributes to the market growth. However, high costs of fibrinolytic drugs, stringent regulations, and risk of bleeding associated with the therapy inhibits the market expansion. The market provides opportunities for development of effective recombinant variants, synthetic analogs, and hybrid molecules with greater specificity, enhanced fibrin specificity and reduced bleeding risks.

However, the high price of these drugs is a key factor that can hinder the market growth.

Key features of the study:

  • This report provides in-depth analysis of the global fibrinolytic therapy market, and provides market size (US$ Bn ) and compound annual growth rate (CAGR %) for the forecast period 2025-2032, considering 2024 as the base year
  • It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
  • This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players
  • It profiles key players in the global fibrinolytic therapy market based on the following parameters - company highlights, products portfolio, key highlights, financial performance, and strategies
  • Key companies covered as a part of this study include Genentech, Inc. (Roche), Bayer AG, Boehringer Ingelheim International GmbH, Pfizer Inc., Bristol Myers Squibb Company, Novartis AG, AstraZeneca PLC, Johnson & Johnson, Daiichi Sankyo Company, Limited, Merck & Co., Inc., Sanofi S.A., Takeda Pharmaceutical Company Limited, Abbott Laboratories, Mallinckrodt Pharmaceuticals, and Mitsubishi Tanabe Pharma Corporation
  • Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
  • Global fibrinolytic therapy market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
  • Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global fibrinolytic therapy market

Detailed Segmentation:

  • Global Fibrinolytic Therapy Market, By Drug Type:
    • Alteplase
    • Reteplase
    • Tenecteplase
    • Streptokinase
    • Anistreplase
    • Urokinase
  • Global Fibrinolytic Therapy Market, By Indication:
    • Acute Ischemic Stroke
    • Acute Myocardial Infarction
    • Deep Vein Thrombosis
    • Peripheral Arterial Thrombosis
    • Other Arterial Thrombosis
  • Global Fibrinolytic Therapy Market, By End User:
    • Hospitals
    • Ambulatory Surgical Centers
    • Specialty Clinics
    • Others
  • Global Fibrinolytic Therapy Market, By Administration:
    • Intravenous (IV)
    • Intra-arterial (IA)
  • Global Fibrinolytic Therapy Market, By Distribution Channel:
    • Hospital Pharmacies
    • Retail Pharmacies
    • Online Pharmacies
  • Global Fibrinolytic Therapy Market, By Patient Age:
    • Adult Patients
    • Pediatric Patients
  • Global Fibrinolytic Therapy Market, By Packaging Type:
    • Vials
    • Ampoules
    • Pre-filled Syringes
  • Global Fibrinolytic Therapy Market, By Application:
    • Emergency Care
    • Interventional Cardiology
    • Thrombosis Treatment
    • Others
  • Global Fibrinolytic Therapy Market, By Dosage Form:
    • Lyophilized Powder for Reconstitution
    • Solution for Injection
  • Global Fibrinolytic Therapy Market, By Region:
    • North America
    • Europe
    • Asia Pacific
    • Latin America
    • Middle East
    • Africa
  • Company Profiles
    • Genentech, Inc. (Roche)
    • Bayer AG
    • Boehringer Ingelheim International GmbH
    • Pfizer Inc.
    • Bristol Myers Squibb Company
    • Novartis AG
    • AstraZeneca PLC
    • Johnson & Johnson
    • Daiichi Sankyo Company, Limited
    • Merck & Co., Inc.
    • Sanofi S.A.
    • Takeda Pharmaceutical Company Limited
    • Abbott Laboratories
    • Mallinckrodt Pharmaceuticals
    • Mitsubishi Tanabe Pharma Corporation

Table of Contents

1. Research Objectives and Assumptions

  • Research Objectives
  • Assumptions
  • Abbreviations

2. Market Purview

  • Report Description
    • Market Definition and Scope
  • Executive Summary
    • Market Snippet, By Drug Type
    • Market Snippet, By Indication
    • Market Snippet, By End User
    • Market Snippet, By Administration
    • Market Snippet, By Distribution Channel
    • Market Snippet, By Patient Age
    • Market Snippet, By Packaging Type
    • Market Snippet, By Application
    • Market Snippet, By Dosage Form
    • Market Snippet, By Region
  • Coherent Opportunity Map (COM)

3. Market Dynamics, Regulations, and Trends Analysis

  • Market Dynamics
    • Driver
  • Increasing incidence of cardiovascular diseases
  • Growing geriatric population
  • Technological advancements
  • Access to healthcare facilities
    • Restrain
  • Limited efficacy in certain patient populations
  • Risk of bleeding complications
  • Availability of alternative treatment modalities
  • Time sensitivity and door-to-needle delays
    • Opportunities
  • Emerging markets
  • Combination therapies
  • Telemedicine and remote treatment
  • Personalized medicine
    • Key Highlights
    • Regulatory Scenario
    • Recent Trends
    • Product Launches/Approvals
    • PEST Analysis
    • PORTER's Analysis
    • Mergers, Acquisitions, and Collaborations

4. Global Fibrinolytic Therapy Market - Impact of Coronavirus (COVID-19) Pandemic

  • COVID-19 Epidemiology
  • Supply Side and Demand Side Analysis
  • Economic Impact

5. Global Fibrinolytic Therapy Market, By Drug Type, 2020-2032, (US$ Bn)

  • Introduction
    • Market Share Analysis, 2020 and 2032 (%)
    • Y-o-Y Growth Analysis, 2021 - 2032
    • Segment Trends
  • Alteplase
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2020-2032,(US$ Bn)
  • Reteplase
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2020-2032,(US$ Bn)
  • Tenacteplase
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2020-2032,(US$ Bn)
  • Streptokinase
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2020-2032,(US$ Bn)
  • Anistreplase
    • Introduction
    • Size and Forecast, and Y-o-Y Growth, 2020-2032,(US$ Bn)
  • Urokinase
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2020-2032,(US$ Bn)

6. Global Fibrinolytic Therapy Market, By Indication, 2020-2032, (US$ Bn)

  • Introduction
    • Market Share Analysis, 2020 and 2032 (%)
    • Y-o-Y Growth Analysis, 2021 - 2032
    • Segment Trends
  • Acute Ischemic Stroke
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2020-2032,(US$ Bn)
  • Acute Myocardial Infarction
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2020-2032,(US$ Bn)
  • Deep Vein Thrombosis
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2020-2032,(US$ Bn)
  • Peripheral Arterial Thrombosis
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2020-2032,(US$ Bn)
  • Other Arterial Thrombosis
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2020-2032,US$ Bn(US$ Bn)

7. Global Fibrinolytic Therapy Market, By End User, 2020-2032, (US$ Bn)

  • Introduction
    • Market Share Analysis, 2020 and 2032 (%)
    • Y-o-Y Growth Analysis, 2021 - 2032
    • Segment Trends
  • Hospitals
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2020-2032,(US$ Bn)
  • Ambulatory Surgical Centers
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2020-2032,(US$ Bn)
  • Speciality Clinics
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2020-2032,(US$ Bn)
  • Others
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2020-2032,(US$ Bn)

8. Global Fibrinolytic Therapy Market, By Administration, 2020-2032, (US$ Bn)

  • Introduction
    • Market Share Analysis, 2020 and 2032 (%)
    • Y-o-Y Growth Analysis, 2021 - 2032
    • Segment Trends
  • Intravenous (IV)
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2020-2032,(US$ Bn)
  • Intra-arterial (IA)
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2020-2032,(US$ Bn)

9. Global Fibrinolytic Therapy Market, By Distribution Channel, 2020-2032, (US$ Bn)

  • Introduction
    • Market Share Analysis, 2020 and 2032 (%)
    • Y-o-Y Growth Analysis, 2021 - 2032
    • Segment Trends
  • Hospital Pharmacies
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2020-2032,(US$ Bn)
  • Retail Pharmacies
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2020-2032,(US$ Bn)
  • Online Pharmacies
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2020-2032,(US$ Bn)

10. Global Fibrinolytic Therapy Market, By Patient Age, 2020-2032, (US$ Bn)

  • Introduction
    • Market Share Analysis, 2020 and 2032 (%)
    • Y-o-Y Growth Analysis, 2021 - 2032
    • Segment Trends
  • Adult Patients
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2020-2032,(US$ Bn)
  • Pediatric Patients
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2020-2032,(US$ Bn)

11. Global Fibrinolytic Therapy Market, By Packaging Types, 2020-2032, (US$ Bn)

  • Introduction
    • Market Share Analysis, 2020 and 2032 (%)
    • Y-o-Y Growth Analysis, 2021 - 2032
    • Segment Trends
  • Vials
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2020-2032,(US$ Bn)
  • Ampoules
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2020-2032,(US$ Bn)
  • Pre-filled Syringes
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2020-2032,(US$ Bn)

12. Global Fibrinolytic Therapy Market, By Application, 2020-2032, (US$ Bn)

  • Introduction
    • Market Share Analysis, 2020 and 2032 (%)
    • Y-o-Y Growth Analysis, 2021 - 2032
    • Segment Trends
  • Emergency Care
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2020-2032,(US$ Bn)
  • Interventional Cardiology
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2020-2032,(US$ Bn)
  • Thrombosis Treatment
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2020-2032,(US$ Bn)
  • Others
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2020-2032,(US$ Bn)

13. Global Fibrinolytic Therapy Market, By Dosage Form, 2020-2032, (US$ Bn)

  • Introduction
    • Market Share Analysis, 2020 and 2032 (%)
    • Y-o-Y Growth Analysis, 2021 - 2032
    • Segment Trends
  • Lyophilized Powder for Reconstitution
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2020-2032,(US$ Bn)
  • Solution for Injection
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2020-2032,(US$ Bn)

14. Global Fibrinolytic Therapy Market, By Region, 2020-2032, (US$ Bn)

  • Introduction
    • Market Share Analysis, By Region, 2020 and 2032 (%)
    • Y-o-Y Growth Analysis, For Region, 2021 -2032
    • Country Trends
  • North America
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, By Drug Type, 2020-2032,(US$ Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By Indication, 2020-2032,(US$ Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By End User, 2020-2032,(US$ Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By Administration, 2020-2032,(US$ Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2020-2032,(US$ Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By Patient Age, 2020-2032,(US$ Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By Packaging Type, 2020-2032,(US$ Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By Application, 2020-2032,(US$ Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By Dosage Form, 2020-2032,(US$ Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By Country, 2020-2032,(US$ Bn)
      • U.S.
      • Canada
  • Europe
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, By Drug Type, 2020-2032,(US$ Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By Indication, 2020-2032,(US$ Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By End User, 2020-2032,(US$ Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By Administration, 2020-2032,(US$ Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2020-2032,(US$ Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By Patient Age, 2020-2032,(US$ Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By Packaging Type, 2020-2032,(US$ Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By Application, 2020-2032,(US$ Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By Dosage Form, 2020-2032,(US$ Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By Country, 2020-2032,(US$ Bn)
      • Germany
      • U.K.
      • France
      • Italy
      • Spain
      • Russia
      • Rest of Europe
  • Asia Pacific
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, By Drug Type, 2020-2032,(US$ Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By Indication, 2020-2032,(US$ Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By End User, 2020-2032,(US$ Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By Administration, 2020-2032,(US$ Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2020-2032,(US$ Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By Patient Age, 2020-2032,(US$ Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By Packaging Type, 2020-2032,(US$ Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By Application, 2020-2032,(US$ Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By Dosage Form, 2020-2032,(US$ Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By Country, 2020-2032,(US$ Bn)
      • China
      • India
      • Japan
      • Australia
      • South Korea
      • ASEAN
      • Rest of Asia Pacific
  • Latin America
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, By Drug Type, 2020-2032,(US$ Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By Indication, 2020-2032,(US$ Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By End User, 2020-2032,(US$ Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By Administration, 2020-2032,(US$ Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2020-2032,(US$ Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By Patient Age, 2020-2032,(US$ Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By Packaging Type, 2020-2032,(US$ Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By Application, 2020-2032,(US$ Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By Dosage Form, 2020-2032,(US$ Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By Country, 2020-2032,(US$ Bn)
      • Brazil
      • Mexico
      • Argentina
      • Rest of Latin America
  • Middle East
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, By Drug Type, 2020-2032,(US$ Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By Indication, 2020-2032,(US$ Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By End User, 2020-2032,(US$ Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By Administration, 2020-2032,(US$ Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2020-2032,(US$ Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By Patient Age, 2020-2032,(US$ Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By Packaging Type, 2020-2032,(US$ Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By Application, 2020-2032,(US$ Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By Dosage Form, 2020-2032,(US$ Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By Country, 2020-2032,(US$ Bn)
      • GCC Countries
      • Israel
      • Rest of Middle East
  • Africa
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, By Drug Type, 2020-2032,(US$ Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By Indication, 2020-2032,(US$ Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By End User, 2020-2032,(US$ Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By Administration, 2020-2032,(US$ Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2020-2032,(US$ Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By Patient Age, 2020-2032,(US$ Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By Packaging Type, 2020-2032,(US$ Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By Application, 2020-2032,(US$ Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By Dosage Form, 2020-2032,(US$ Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By Country/Region, 2020-2032,(US$ Bn)
      • South Africa
      • Central Africa
      • North Africa

15. Competitive Landscape

  • Company Profile
    • Genentech, Inc. (Roche)
  • Company Highlights
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies
    • Bayer AG
  • Company Highlights
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Strategies
    • Boehringer Ingelheim International GmbH
  • Company Highlights
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Strategies
    • Pfizer Inc.
  • Company Highlights
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Strategies
    • Bristol Myers Squibb Company
  • Company Highlights
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Strategies
    • Novarts AG
  • Company Highlights
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Strategies
    • AstraZeneca PLC
  • Company Highlights
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Strategies
    • Johnson & Johnson
  • Company Highlights
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Strategies
    • Daiichi Sankyo Company, Limited
  • Company Highlights
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Strategies
    • Merck & Co., Inc.
  • Company Highlights
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Strategies
    • Sanofi S.A.
  • Company Highlights
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Strategies
    • Takeda Pharmaceutical Company Limited
  • Company Highlights
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Strategies
    • Abbott Laboratories
  • Company Highlights
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Strategies
    • Mallinckrodt Pharmaceuticals
  • Company Highlights
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Strategies
    • Mitsubishi Tanabe Pharma Corporation
  • Company Highlights
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Strategies
  • Analyst Views

16. Section

  • References
  • Research Methodology
  • About us